Cantor Fitzgerald Reiterates Overweight Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Cantor Fitzgerald reissued their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIOFree Report) in a research report released on Monday morning, Benzinga reports.

A number of other research analysts also recently commented on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, May 29th. The Goldman Sachs Group boosted their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a report on Tuesday, June 4th. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an outperform rating in a research note on Tuesday, June 4th. Finally, JPMorgan Chase & Co. reiterated a neutral rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Hold and an average target price of $50.67.

Read Our Latest Stock Report on Agios Pharmaceuticals

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $42.56 on Monday. The company has a 50 day moving average price of $36.23 and a two-hundred day moving average price of $29.60. The stock has a market capitalization of $2.42 billion, a P/E ratio of -6.73 and a beta of 0.77. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $49.06.

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business’s revenue was up 46.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.47) earnings per share. Research analysts forecast that Agios Pharmaceuticals will post -5.57 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now directly owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 5,040 shares during the last quarter. NEOS Investment Management LLC bought a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. Entropy Technologies LP bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at approximately $286,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 942 shares during the last quarter.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

See Also

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.